To address the global burden of sickle cell disease (SCD) and the need for novel therapies,
the American Society of Hematology partnered with the US Food and Drug Administration to …

Pain in sickle cell disease (SCD) is associated with increased morbidity, mortality, and high
health care costs. Although episodic acute pain is the hallmark of this disorder, there is an …

Pain is a major comorbidity of sickle cell disease (SCD). Patients with SCD may suffer from
both acute and chronic pain. Acute pain is caused by recurrent and unpredictable episodes …

Sustained donor engraftment after allogeneic hematopoietic cell transplantation (HCT)
converts to healthy donor hemoglobin synthesis and halts disease symptoms in patients with …

Objective Pain sensitization may contribute to pain severity in rheumatoid arthritis (RA),
impacting disease activity assessment. We examined whether pain processing mechanisms …

Vaso-occlusive pain episodes (VOE) cause severe pain in patients with sickle cell disease
(SCD). Vaso-occlusive events promote ischemia/reperfusion pathobiology that activates …

Chronic opioid therapy is a common treatment regimen for patients with sickle cell disease
(SCD), a chronically painful recessive hemoglobinopathy. The collective risk profile of …

Pain is the most frequently occurring complication of sickle cell disease (SCD) and the
leading cause of hospitalizations for affected individuals. Acute pain episodes are also an …

Epidemiological studies suggest that women are not only at a higher risk for developing
knee osteoarthritis (KOA), but also report greater symptom severity compared to men. One …

Endothelial dysfunction underlies the pathobiology of cerebrovascular disease. Mast cells
are located in close proximity to the vasculature, and vasoactive mediators released upon …